Welcome to the FOURTH 2020 Issue of The CLL Society Tribune:
CAR-T Special Edition
Yogi Berra is reported to have said, “It’s tough to make predictions, especially about the future.” How many of us saw COVID-19 coming? And then saw it staying around for nine months and counting, like some unwelcome house guest who never leaves? I will make no predictions concerning 2021 in general. But I am grateful to still be here with my loved ones, even if here means being socially isolated. My predictions are that in 2021 CAR-T therapy will be increasingly used for CLL and other blood cancers, will become even safer and more effective, and in the not-too-distant future will be considered a smart treatment option. In our final CLL Society Tribune for 2020, we have experts and patients sharing their CAR-T journeys. You will also read about those who are not only trying to catch a glimpse of the future, but also inventing new cellular therapies and combining them with other treatments to improve outcomes. Not just in the CLL space, but for other leukemias and lymphomas as well. There are reasons to be optimistic, as there is a whole lot of light at the end of this very long tunnel. Hold on! The future is bright. My own story with CAR-T serves as living proof of how well this therapy can work. Happy Holidays and may this season of miracles bring the miracle of peace and health to us all. Stay safe. Stay strong. We are all in this together.
Brian Koffman, MDCM (retired) co-founder, EVP and CMO CLL Society and CLL and CAR-T patient
Learn more about CAR-T and other cellular therapies by visiting our webpage here.
CLL Tribune is looking for your contribution including articles, storytelling, poems, drawings, or other creative mediums. Please share!
Email firstname.lastname@example.org with your interest!
Dr. Acharya dives deep into the explanation of CAR-T therapy, the current challenges, and what the future holds. Read more
At ASH 2019 in Orlando, Dr. Brian Koffman interviewed Dr. David Maloney about the future of CAR-T as it begins to move up in the treatment pathway. Watch The Interview
At iwCLL 2019 in Edinburgh, Scotland, Dr. Brian Koffman catches up with Dr. David Maloney about the advantages and concerns of allogeneic CAR-T. Watch The Interview
Dr. Brian Koffman, Chief Medical Officer of the CLL Society, answers readers’ questions submitted to the CLL Society. Read more
Questions submitted by readers and answered by our CLL Society experts.
By Richard Furman, MD
Dr. Richard Furman of Weill-Cornell Medical College answers readers’ questions submitted to the CLL Society. Read more
Thomas E Henry III, MBA, RPh, CPh from Burlington Consulting Associates answers readers’ pharmacy questions submitted to the CLL Society. Read more
Susan J. Leclair from University of Massachusetts Dartmouth answers readers’ lab scientist questions submitted to the CLL Society. Read more
The CLL Society Tribune is made possible in part by grant support from AbbVie, Astra Zeneca, Bristol Meyers Squibb, and Genentech.
The CLL Society does not provide medical advice or endorsements. Unless explicitly stated otherwise, all content in the CLL Tribune is the opinion or information of its author, not the CLL Society. This newsletter is for reference and educational purposes only and is not a substitute for medical advice. We do not guarantee the accuracy of any of the materials. Always contact your own doctor or other professional healthcare provider if you have any questions concerning your or your family’s health. Everyone’s circumstances are different.